Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 5/20 | 0.48 |
| ▸ | RAB9A | P51151 | 5/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.48 |
| ▸ | NFKB1 | P19838 | 4/20 | 0.48 |
| ▸ | NFKB2 | Q00653 | 4/20 | 0.48 |
| ▸ | RELA | Q04206 | 4/20 | 0.48 |
| ▸ | MAPT | P10636 | 4/20 | 0.48 |
| ▸ | PKM | P14618 | 1/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.45 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.45 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.45 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.45 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.45 |
| ▸ | RECQL | P46063 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.42 |
| ▸ | CASP3 | P42574 | 4/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.32 |
| ▸ | MEN1 | O00255 | 2/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3340137 | 0.83 | NPC1 (0.55) | NPC1RAB9ASMN1; SMN2NFKB1NFKB2 | |
| SCHEMBL3343195 | 0.82 | NPC1 (0.47) | NPC1RAB9ASMN1; SMN2NFKB1NFKB2 | |
| SCHEMBL3340419 | 0.81 | NPC1 (0.57) | NPC1RAB9ASMN1; SMN2NFKB1NFKB2 | |
| SCHEMBL3338543 | 0.79 | NPC1 (0.60) | NPC1RAB9ASMN1; SMN2NFKB1NFKB2 | |
| SCHEMBL3340463 | 0.78 | NPC1 (0.62) | NPC1RAB9ASMN1; SMN2NFKB1NFKB2 | |
| SCHEMBL3343693 | 0.77 | NPC1 (0.57) | NPC1RAB9ASMN1; SMN2NFKB1NFKB2 | |
| SCHEMBL3343142 | 0.76 | NPC1 (0.48) | NPC1RAB9ASMN1; SMN2NFKB1NFKB2 | |
| SCHEMBL3340394 | 0.76 | SMN1; SMN2 (0.55) | NPC1RAB9ASMN1; SMN2NFKB1NFKB2 | |
| SCHEMBL3340402 | 0.76 | NPC1 (0.53) | NPC1RAB9ASMN1; SMN2NFKB1NFKB2 | |
| SCHEMBL3339077 | 0.76 | NPC1 (0.47) | NPC1RAB9ASMN1; SMN2NFKB1NFKB2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100160369-A1 | S1P1 Agonists and Methods of Making And Using | EXELIXIS, INC. (US) | 2010-06-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100160369-A1 | S1P1 Agonists and Methods of Making And Using | S1PR1, S1PR5, S1PR3 | NPC1 241/4885RAB9A 2844/4885SMN1; SMN2 2046/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.